In patients with HER2-positive breast cancer, the updated PREDICT tool provided better estimates of overall survival and breast cancer-specific survival than the other two models, emphasising the importance of HER2 status in prognostication (14). This evidence concerns the gene ERBB2 and breast carcinoma.